UTHR at a glance
UNITED THERAPEUTICS Corp (UTHR, SEC CIK 1082554) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion (up 10.6% from FY2024) and net income of $1.3 billion. Diluted EPS was $27.86.
- As of June 30, 2026, 40 institutional investment managers tracked by SignalX reported holding UNITED THERAPEUTICS Corp (UTHR) shares worth $10.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ROTHBLATT MARTINE A on October 5, 2026 of 501 shares at $536.26 per share.
- In the last 90 days, UTHR insiders reported 0 open-market purchases ($0) and 753 open-market sales ($329.9M) on Form 4, a net sale of $329.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.2B
- +10.6% vs prior year
- Insiders · 90 days
- 0 buys · 753 sells
- Net −$329.9M
- 13F holders
- 40 funds
- $10.2B · +1 vs prior quarter
- Latest 10-Q
- Aug 5, 2026
- Quarterly report
SignalX for UTHR
Don't miss the next UTHR filing
- Alerts as it files. A push when UTHR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut UTHR, by share count.
- Ask anything. An AI agent that reads every UTHR filing and answers with sources.
UTHR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| ROTHBLATT MARTINE A | M | Oct 5, 2026 | 9,500 | $117.76 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 501 | $536.26 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 905 | $537.43 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 655 | $538.62 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 931 | $539.50 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 1,028 | $540.50 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 1,239 | $541.66 |
| ROTHBLATT MARTINE A | Sell | Oct 5, 2026 | 918 | $542.56 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.9B | $3.2B |
| Gross Profit | - | $2.6B | $2.8B |
| Operating Income | - | $1.4B | $1.5B |
| Net Income | - | $1.2B | $1.3B |
| Gross Margin | - | 89.2% | 87.9% |
| Op. Margin | - | 47.9% | 46.9% |
| Net Margin | - | 41.5% | 41.9% |
| Balance Sheet | |||
| Total Assets | $7.2B | $7.4B | $7.9B |
| Equity | $6.0B | $6.4B | $7.1B |
| ROE | - | 18.5% | 18.8% |
| Per Share | |||
| EPS | - | $24.64 | $27.86 |
| Cash Flow | |||
| Operating CF | - | $1.3B | $1.6B |
| CapEx | - | $246.5M | $520.5M |
Source: XBRL data in UNITED THERAPEUTICS Corp (UTHR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate UTHR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 40 | $10.20B |
| Q1 2026 | 39 | $11.55B |
| Q4 2025 | 36 | $9.44B |
| Q3 2025 | 36 | $8.82B |
| Q2 2025 | 35 | $5.84B |
| Q1 2025 | 33 | $4.52B |
| Q4 2024 | 29 | $4.93B |
| Q3 2024 | 26 | $2.81B |
- Millennium Management+255.7K (+167%)
- Franklin Resources+62.3K (+22%)
- State Street Corp+54.1K (+3%)
- Goldman Sachs Group+51.6K (+45%)
- Ameriprise Financial+32.0K (+35%)
- AQR Capital Management−280.2K (-34%)
- T. Rowe Price Group−162.0K (-40%)
- Invesco Ltd−135.3K (-22%)
- BlackRock−105.1K (-2%)
- Vanguard Portfolio Management LLC−84.3K (-4%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 274 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
UTHR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
UTHR SEC filings: frequently asked questions
Are UTHR insiders buying or selling?
In the last 90 days, UNITED THERAPEUTICS Corp (UTHR) officers, directors and 10% owners reported no open-market purchases and 753 open-market sales worth $329.9 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold UTHR stock?
As of June 30, 2026, the largest UNITED THERAPEUTICS Corp (UTHR) holders among the 13F filers tracked by SignalX were BlackRock ($2.9 billion), Vanguard Portfolio Management LLC ($1.0 billion), Vanguard Capital Management LLC ($1.0 billion), State Street Corp ($1.0 billion), Renaissance Technologies LLC ($925.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was UTHR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion (up 10.6% from FY2024) and net income of $1.3 billion. Diluted EPS was $27.86. The figures come from the XBRL data in the 10-K.
What are the latest UTHR SEC filings?
UNITED THERAPEUTICS Corp (UTHR) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on October 6, 2026.
What is UTHR's SEC CIK number?
UNITED THERAPEUTICS Corp (UTHR)'s SEC Central Index Key (CIK) is 1082554. EDGAR lists every UTHR filing under that number.
Ask anything about UTHR
The research agent reads UTHR's filings, financials, insider trades and 13F holders, then answers with sources.